Merz, Kvvit strike China-region deal for INBRIJA: full analysis
Version 2
Merz Therapeutics is expanding the geographic ambitions for INBRIJA through a new exclusive agreement with Jiangxi Kvvit Pharmaceutical, covering mainland China, Hong Kong, and Macao. The May 25, 2026 Business Wire announcement says Kvvit will lead local development, regulatory activities, and commercialization of the inhaled levodopa therapy, while Merz retains manufacturing and is set to receive upfront, milestone, supply, and royalty payments. (businesswire.com)
The product itself is not new, but the territory expansion is. INBRIJA is an inhaled levodopa powder used for intermittent treatment of Parkinson’s “OFF” episodes in adults already receiving levodopa plus a dopa-decarboxylase inhibitor. It has been authorized in the U.S. since 2018 and in the European Union since 2019, giving Merz and Kvvit a foundation of prior regulatory and commercial experience as they move into Greater China. (accessdata.fda.gov)
That background matters because INBRIJA occupies a specific niche in Parkinson’s care: rescue treatment when routine oral therapy wears off and symptoms return. Published reviews of the clinical development program describe the inhaled formulation as a way to deliver levodopa rapidly through the lungs, helping bypass gastrointestinal variability that can complicate oral dosing. EMA materials cite clinical data showing symptom improvement within the OFF-period setting, including measurable benefit 30 minutes after dosing in pivotal studies. (pmc.ncbi.nlm.nih.gov)
In the deal announcement, Merz framed the partnership as a route to bring the product to people living with Parkinson’s disease in Greater China, while Kvvit positioned the agreement as a way to strengthen its central nervous system portfolio. The release did not disclose the financial terms or a filing date, but it did make clear that Kvvit’s role spans development, regulatory execution, and commercialization, without manufacturing rights. (businesswire.com)
Outside the announcement, the broader market context helps explain the move. Parkinson’s disease represents a substantial and aging-care challenge in China, and published epidemiology studies continue to point to a meaningful patient population among older adults. For Merz, that creates a rationale for using a local partner with on-the-ground regulatory and commercial capabilities rather than building the market alone. That kind of regional licensing structure is common in pharma, especially where local registration strategy and market access can be decisive. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this story is less about Parkinson’s treatment itself and more about how specialty therapeutics are being globalized. It highlights several trends worth watching across animal health and human pharma alike: growing reliance on regional commercialization partners, continued interest in inhaled and device-enabled drug delivery, and the strategic importance of China, Hong Kong, and Macao as expansion markets. For companies serving pet parents and veterinary teams, the same themes, regulatory localization, partner-led market entry, and differentiated delivery technology, increasingly shape licensing and launch decisions. (businesswire.com)
What to watch: The next signals will be whether Kvvit outlines a regulatory submission path, whether local studies are required before approval, and how quickly the partners can move from licensing to launch. Any future disclosures on milestone timing, pricing strategy, or physician education plans will offer a clearer read on how serious and near-term the China opportunity is for INBRIJA. (businesswire.com)